Kimia Biosciences Ltd

A sharp decline in Kimia Biosciences Ltd has pushed the stock to a fresh 52-week low of Rs 24 on 27 Mar 2026, marking a significant 44.19% drop over the past year and a 16.29% fall in just the last two sessions. This downturn comes amid a broader market sell-off, but the stock’s underperformance far exceeds sector and benchmark indices, raising questions about the underlying factors driving this weakness.

Kimia Biosciences Ltd has been downgraded from a Sell to a Strong Sell rating as of 23 March 2026, reflecting deteriorating technical indicators and persistent fundamental weaknesses. Despite some positive quarterly financial results, the company’s overall outlook remains bleak due to high debt levels, poor long-term growth, and underperformance relative to the broader market.

Kimia Biosciences Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 10 March 2026, driven primarily by a shift in technical indicators despite persistent fundamental challenges. The company’s Mojo Score improved to 34.0, reflecting a modestly less negative outlook, while the Mojo Grade moved from Strong Sell to Sell. This article analyses the four key parameters influencing this rating change: Quality, Valuation, Financial Trend, and Technicals.

Kimia Biosciences Ltd has been downgraded from a Sell to a Strong Sell rating as of 2 March 2026, reflecting deteriorating technical indicators and persistent fundamental weaknesses. Despite some positive quarterly financial results, the company’s long-term growth prospects remain subdued, compounded by high leverage and underperformance relative to the broader market.

Kimia Biosciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 15 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Kimia Biosciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 15 February 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock's current position as of 19 February 2026, providing investors with the latest insights into the company’s performance and outlook.

Kimia Biosciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 September 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Kimia Biosciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 Sep 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 28 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Kimia Biosciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 September 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 05 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Kimia Biosciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 Sep 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 December 2025, providing investors with an up-to-date view of the company's fundamentals, returns, and market performance.

Kimia Bioscien., a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting shifts in its fundamental and technical outlook. This adjustment follows a detailed reassessment of the company’s quality, valuation, financial trends, and technical indicators, highlighting ongoing challenges in its operational and market performance.

Kimia Biosciences touched a fresh 52-week low of Rs.26.09 today, marking a significant decline amid a sustained downward trend. The stock has experienced notable volatility and underperformance relative to its sector and benchmark indices over the past year.

Kimia Biosciences has reached a new 52-week low of Rs.27.2, marking a significant decline in its stock price amid a sustained downward trend over recent days. The pharmaceutical and biotechnology company’s shares have underperformed relative to its sector and broader market indices, reflecting ongoing pressures on its valuation and financial metrics.

Kimia Biosciences has reached a new 52-week low of Rs.27.2 today, marking a significant decline in its stock price amid a sustained downward trend over recent sessions. The pharmaceutical and biotechnology company’s shares have underperformed both its sector and broader market indices, reflecting ongoing pressures on its valuation and financial metrics.

Kimia Biosciences has reached a new 52-week low of Rs.28.4 today, marking a significant decline in its stock price amid ongoing downward momentum. The stock has experienced notable volatility and underperformance relative to its sector and benchmark indices.

Kimia Biosciences Ltd., a Gurgaon-based pharmaceutical company specialising in bulk drug manufacturing, reported net profit of ₹1.02 crores for Q2 FY26, marking a sequential increase of 70.00% from ₹0.60 crores in Q1 FY26. However, year-on-year comparison reveals a concerning decline of 36.65% from ₹1.61 crores in Q2 FY25. The company's stock, trading at ₹34.00 with a modest market capitalisation of ₹159 crores, has struggled significantly, declining 27.66% over the past year whilst the broader Sensex gained 9.48%.